Induction immunochemotherapy followed by definitive radiotherapy for inoperable NSCLC: A retrospectivecohort study
Cancer Treatment and Research Communications · 2026 · 49 · 101423
DOI: 10.1016/j.ctarc.2026.101423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Jiuyang Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sichuan Cancer Hospital, School of Medicine, University of Electronic Science and Technology of China; Chengdu China. Departm…. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: For patients with unresectable stage III non-small cell lung cancer, consolidation immunotherapy after concurrent or sequential chemoradiotherapy has become the standard treatment paradigm. However, in real-world clinical practice, a considerable proportion of patients are unable to tolerate the standard concurrent chemoradiotherapy regimen due to high tumor burden, advanced age, poor performance status, multiple comorbidities, or early toxicities from chemoradiotherapy. These factors not only limit the safe escalation of radiotherapy doses but also increase the risk of treatment-related mortality and severe complications. Therefore, there is an urgent need to explore alternative treatment strategies. METHODS: We retrospectively reviewed patients with histologically or cytologically confirmed stage III unresectable non-small cell lung cancer who received treatment at Sichuan Cancer Hospital between January 2022 and August 2024. The primary endpoints are PFS and OS, while the secondary endpoints are ORR and safety. RESULTS: A total of 87 patients were included. The median follow-up time from the start of induction therapy was 21months. The 1-year PFS rate and OS rate were 70% and 88.5%, respectively. The median PFS and median OS was NR at the time of data cutoff. ORR was 82.8%. Immunotherapy consolidation was associated with both improved PFS and OS. The incidence rate of pneumonia above grade 3 was 8%. CONCLUSIONS: The treatment approach of induction ICIs combined with chemotherapy followed by definitive radiotherapy, with or without consolidation immunotherapy, has shown encouraging efficacy and is safe to administer, but further research is still needed to confirm these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Sichuan Cancer Hospital, School of Medicine, University of Electronic Science and Technology of China; Chengdu China. Department of Oncology, Chengdu Medical College, Chengdu, China.
- Department of Oncology, Sichuan Cancer Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of…
- Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electroni…
Zitieren
APA
Chen, J., Li, N., Yang, X., Yao, W., Wei, Y., Wang, Q., & Li, X. (2026). Induction immunochemotherapy followed by definitive radiotherapy for inoperable NSCLC: A retrospectivecohort study. Cancer Treatment and Research Communications, 49, 101423. https://doi.org/10.1016/j.ctarc.2026.101423
Vancouver
Chen J, Li N, Yang X, Yao W, Wei Y, Wang Q, et al. Induction immunochemotherapy followed by definitive radiotherapy for inoperable NSCLC: A retrospectivecohort study. Cancer Treatment and Research Communications. 2026;49:101423. doi:10.1016/j.ctarc.2026.101423
BibTeX
@article{Chen2026,
author = {Chen, Jiuyang and Li, Nanxi and Yang, Xi and Yao, Wenxiu and Wei, Yang and Wang, Qifeng and Li, Xin},
title = {Induction immunochemotherapy followed by definitive radiotherapy for inoperable NSCLC: A retrospectivecohort study},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {49},
pages = {101423},
doi = {10.1016/j.ctarc.2026.101423}
}
EUVIMED